📌 Key Takeaways
- Topic: Silica Supplier Middle East: Sourcing Options, Logistics and Key Markets
- Keywords: silica abrasive
- Published: 2026-11-20 07:33:01
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Alumina Powder vs Silica Powder: Properties, Uses and How to Choose
- Silica in Cosmetics: Functions, Types and Safety
- What Is Silicosis? Causes, Symptoms, Prevention and Silica Exposure
- Scratch Resistant Silica: How It Improves Coating Hardness and Durability
- As an important branch in the field of inorganic nanomedicines, noble metal NPs have attracted widespread interest in the biomedical field from the very beginning. Noble metal NPs have made promising progress in areas including bioimaging, 124, 125 photothermal tumor ablation, 126, 127, 128 PDT, 20, 129, 130 radiotherapy sensitization, 131, 132 and lately developed nanozyme-based catalytic therapy, 133, 134, 135 because of their tunable optical properties, excellent catalytic activity and good biocompatibility. Among those noble metal NPs, ruthenium (Ru), 136 palladium (Pd), 137, 138 silver (Ag), 139, 140 platinum (Pt), 141, 142 and gold (Au) 143, 144 NPs have been reported to be loaded into MSNs to form various noble metal NPs/MSNs nanocomposites for biomedical applications (Fig. 4b ). Of them, Au and Ag NPs are the most studied due to their relatively well-established synthetic routes, relatively high earthly reserves and good safety profiles. 145
- 2500 Mesh Silica: Particle Size, Specifications and Common Applications
Silica Matting Agent: How It Works, Key Specs and How to Choose the Right Grade
What is silica (SiO₂)?
quartz flour
What is the difference between fumed silica and precipitated silica?
silica sol Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
What drives silica raw material prices?
silica desiccant
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.